Alpha-lipoic acid (ALA) has 2 documented interactions in Magellan’s curated dataset, covering Diabetes medications, Thyroid medication (levothyroxine). Each entry below gives the mechanism as the cited reference states it, the direction the risk runs, how serious that reference treats it, and what to actually do about it — which is, in every case, a conversation with the clinician or pharmacist who manages the prescription rather than a decision you make alone.
What it is. Alpha-lipoic acid (ALA), also called thioctic acid, is a naturally occurring sulfur-containing compound synthesized in mitochondria, where it serves as an essential cofactor for enzymes that convert nutrients into cellular energy. Being both water- and fat-soluble, ALA and its reduced form dihydrolipoic acid act as broad-spectrum, so-called universal antioxidants that scavenge free radicals, chelate metals, and regenerate other antioxidants such as vitamins C and E.
Where it sits on the evidence. Magellan grades the supplement itself as Moderate evidence, with a typical studied dose of 300–600 mg/day typical (600 mg/day optimal for neuropathy symptoms); up to 1,800 mg/day used in trials. That grade is about whether it works, not about whether it is safe alongside your medication — the two questions are independent, and this page answers only the second.
Products this covers: Alpha-Lipoic Acid (ALA).
How the risks cluster. Every entry on this page runs through the same mechanism — additive — which means one conversation covers all of them.
Safety and efficacy are separate questions, and this page only answers the first. For the second, the study Magellan’s coverage of Alpha-lipoic acid rests on is:
“In the 4-year NATHAN 1 trial, ALA improved neuropathy symptoms but did not significantly improve the primary neuropathy-impairment composite, leaving disease modification unproven.”
A strong result does not make a supplement safe alongside your prescription, and a documented interaction does not mean the supplement does not work. Magellan grades those two things separately, and neither grade moves for a commission.
Magellan’s Medication Safety Check runs entirely on your device — type the medicines you take and it flags every documented interaction in this dataset. Nothing you type is sent anywhere.
Open the Medication Safety Check →Alpha-lipoic acid can lower blood sugar; combined with diabetes medication this may add to the glucose-lowering effect and raise hypoglycemia risk.
Medicines in this group include: Metformin (Glucophage, Fortamet), Insulin (Humalog, Novolog), Glipizide (Glucotrol), Glyburide (Diabeta, Glynase), Glimepiride (Amaryl), Sitagliptin (Januvia), Empagliflozin (Jardiance), Dapagliflozin (Farxiga) and 5 more.
Mayo Clinic advises against using alpha-lipoic acid together with thyroid hormone medication, as the supplement might affect how well the thyroid medicine works.
Medicines in this group include: Levothyroxine (Synthroid, Levoxyl), Liothyronine (Cytomel), Desiccated thyroid (Armour thyroid, Np thyroid).
These are the warning signs that go with the medication classes on this page. They are general safety-netting, not a prediction that any supplement will cause them.
If something feels seriously wrong, do not wait for an appointment. Call 911 (US) or your local emergency number.
Severity describes the interaction as the cited reference frames it, not how a specific person will react. A “minor” entry in someone with kidney disease, on five other drugs, can matter more than a “major” one in someone on nothing else.
This is a curated set of interactions with citations — not an exhaustive pharmacology database. An interaction that is absent here has not been ruled out; it may simply not be documented in the references Magellan curates from. Supplements are also not batch-tested for identity or contamination the way prescription drugs are, so what is on the label is a claim rather than a guarantee. And most of these entries come from case reports and mechanistic work rather than randomized trials, which is exactly why the sensible response is a pharmacist review rather than either alarm or dismissal.
9 documented interactions across 9 supplements.
43 documented interactions across 24 supplements.
8 documented interactions · shares a drug class with Alpha-lipoic acid.
7 documented interactions · shares a drug class with Alpha-lipoic acid.
5 documented interactions · shares a drug class with Alpha-lipoic acid.
5 documented interactions · shares a drug class with Alpha-lipoic acid.
The mechanism and the research behind the compound itself.
A–Z of every supplement and drug class in this dataset, plus how to read an interaction.
What the research actually shows, graded independently of affiliate commissions.
Not without checking with the prescriber or pharmacist first. Magellan's dataset grades this as a moderate interaction: Alpha-lipoic acid can lower blood sugar; combined with diabetes medication this may add to the glucose-lowering effect and raise hypoglycemia risk. (Source: Diabetic neuropathy: Can dietary supplements help? - Mayo Clinic.)
2 interactions are documented in Magellan's curated dataset: 2 moderate. They cover Diabetes medications, Thyroid medication (levothyroxine). Absence from this list is not proof of safety — it means no interaction is documented in the references we curate from.
Magellan lists the typical studied dose as: 300–600 mg/day typical (600 mg/day optimal for neuropathy symptoms); up to 1,800 mg/day used in trials. Dose matters for interactions — several of the entries on this page describe effects that only appear at supplemental rather than dietary intakes.